BioNTech's stock faces pressure following a Leerink Partners downgrade, which tempered near-term optimism around its oncology pipeline after a recent rally. The move highlights investor reassessment of catalysts amid mixed long-term performance.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
German Chancellor Friedrich Merz has called for urgent action to dismantle barriers and create a truly integrated European capital market, arguing it is essential for the bloc's economic competitiveness and to keep innovative firms from listing abroad.
The enterprise software giant reported a 19% jump in Q4 cloud revenue, with full-year net income more than doubling. CEO Christian Klein credits AI adoption and the 'RISE with SAP' program as key growth drivers for the coming years.
